bluuebunny/crossref_metadata_2025_split huggingface dataset:
Multilayer Scaling of a Biomimetic Microfluidic Oxygenator
Authors: Vedula Else M. , Isenberg Brett C. , Santos Jose , Lai WeiXuan , Lewis Diana J. , Sutherland David , Roberts Teryn R. , Harea George T. , Wells Christian , Teece Bryan , Urban Joseph , Risoleo Thomas , Solt Derek , Leazer Sahar , Chung Kevin , Sukavaneshvar Sivaprasad , Batchinsky Andriy I. , Borenstein Jeffrey T. 
Published: January 2022

Extracorporeal membrane oxygenation (ECMO) has been advancing rapidly due to a combination of rising rates of acute and chronic lung diseases as well as significant improvements in the safety and efficacy of this therapeutic modality. However, the complexity of the ECMO blood circuit, and challenges with regard to clotting and bleeding, remain as barriers to further expansion of the technology. Recent advances in microfluidic fabrication techniques, devices, and systems present an opportunity to develop new solutions stemming from the ability to precisely maintain critical dimensions such as gas transfer membrane thickness and blood channel geometries, and to control levels of fluid shear within narrow ranges throughout the cartridge. Here, we present a physiologically inspired multilayer microfluidic oxygenator device that mimics physiologic blood flow patterns not only within individual layers but throughout a stacked device. Multiple layers of this microchannel device are integrated with a three-dimensional physiologically inspired distribution manifold that ensures smooth flow throughout the entire stacked device, including the critical entry and exit regions. We then demonstrate blood flows up to 200 ml/min in a multilayer device, with oxygen transfer rates capable of saturating venous blood, the highest of any microfluidic oxygenator, and a maximum blood flow rate of 480 ml/min in an eight-layer device, higher than any yet reported in a microfluidic device. Hemocompatibility and large animal studies utilizing these prototype devices are planned.
Supplemental Visual Abstract, http://links.lww.com/ASAIO/A769.
Attitudes and Intentions of Adult Patients With Cancer Toward Advance Directive: Direct and Indirect Relationships
Authors: Chen Tzu-Ting , Chen Shu-Chen , Hsiao Chia-Chi , Chu Tsui-Ping , Hung Chang-Chiao 
Published: January 2022

Background
Advance directives (ADs) are used to respect the will of patients experiencing a terminal illness regarding preferred medical treatment and to protect their rights. However, the AD completion rate is low.

Objective
The aim of this study was to explore the factors influencing patient intentions toward AD.

Methods
The Theory of Planned Behavior was used as the framework for this study. This study used a cross-sectional design using a face-to-face interview with structured questionnaires. A total of 230 patients with cancer were recruited. Path analysis was used to examine the hypotheses.

Results
Demographic variables were not correlated with patients’ attitudes toward AD. Patients’ knowledge of AD (β = .68, t = 16.15, P < .00) and recognition of important others’ attitudes toward AD (β = .30, t = 10.74, P < .00) were predictors of patients’ attitudes toward AD. Patients’ attitudes toward AD (β = .27, t = 3.74, P < .00) and behavior control over AD (β = .09, t = 1.99, P < .04) predicted patients’ intentions toward AD.

Conclusion
Patients’ knowledge of AD, the patients’ important others’ attitudes, and behavior control toward AD are predictively associated with the intention toward AD completion.

Implications for Practice
Only when patients with cancer are provided an accessible approach for obtaining knowledge regarding AD and are given sufficient time and space can they and their significant others understand the meaning of AD and decide to complete one on their own terms.
Experiences of Symptoms and Impact on Daily Life and Health in Hepatocellular Carcinoma Patients
Authors: Drott Jenny , Björnsson Bergthor , Sandström Per , Berterö Carina 
Published: January 2022

Background
The incidence of hepatocellular cancer (HCC) has continually increased. To achieve optimal supportive cancer care for HCC patients, it is important to consider patients’ experiences and preferences.

Objective
This meta-synthesis aims to critically interpret how patients with HCC experience symptoms and the impact of the disease on daily life and health.

Methods
Searches were performed in the following bibliographic databases: PubMed, CINAHL, Web of Science, Scopus, PsycINFO, and Cochrane Library. In addition, searches were performed using Open Gray to identify relevant studies in the gray literature. The search was limited to studies published in English from 2009 to 2019. Five studies (124 participants) were identified, appraised, and ultimately interpreted and synthesized.

Results
Receiving an HCC diagnosis was overwhelming and affected the patients’ entire lives. Three themes were identified based on the meta-synthesis: (1) disrupted life, (2) living with uncertainty, and (3) a changed body. Patients with HCC experience disrupted lives because of the cancer’s effect on health and multidimensional symptoms.

Conclusion
Available research on the experiences of HCC patients is limited. This meta-synthesis of available studies shows that being given a diagnosis of HCC is an overwhelming event. Our study findings show that an HCC diagnosis affected the individual’s entire life.

Implications for Practice
It is important to identify the patients’ physical, psychological, social, and existential needs during the investigation of their condition, during any curative treatment, and at the palliative stage of the disease.
Barriers and Facilitators to Supportive Care Implementation in Advanced Disease Prostate Cancer Survivors
Authors: Calvo-Schimmel Alejandra , Newman Susan D. , Sterba Katherine R. , Miaskowski Christine , Qanungo Suparna 
Published: January 2022

Background
Individualized supportive care is recommended to manage the debilitating effects of advanced prostate cancer and its treatments. Yet, the implementation of supportive care in practice remains inconsistent.

Objective
The aim of this study was to synthesize the barriers and facilitators to implementing supportive care interventions after identifying supportive care interventions for advanced prostate cancer survivors.

Methods
PubMed, SCOPUS, CINAHL Complete, ProQuest, and PsycINFO were searched for relevant studies published between 2011 and 2020. Studies were included if they reported on a supportive care intervention and included a description of implementation barriers and/or facilitators. The Theoretical Domains Framework was used to characterize implementation barriers and facilitators.

Results
Of the 620 articles identified, 13 met all prespecified inclusion criteria. Primary barriers were related to the domains of environmental context and resources (eg, limited resources), knowledge (eg, insufficient knowledge on efficacy of supportive care), and beliefs about capabilities (eg, lack of confidence in materials). Facilitators fell under environmental context and resources (partnerships with local services), reinforcement (eg, partners inclusion), and skills (eg, delivery by professionals).

Conclusions
This scoping review highlights barriers and facilitators that affect supportive care implementation. Future research that focuses on overcoming barriers and maximizing facilitators is needed to improve, modify, or supplement existing supportive care implementation practices.

Implications for Practice
As the number of advanced prostate cancer survivors continues to increase, supportive care must become the standard of care. Future interventions must incorporate increased knowledge and funding, alternative delivery models, and consistent use of specialty nurses.
Longitudinal Analysis of Sleep Disturbance in Breast Cancer Survivors
Authors: Yang Gee Su , Starkweather Angela R. , Lynch Kelly Debra , Meegan Taylor , Byon Ha Do , Lyon Debra E. 
Published: January 2022

Background
Breast cancer survivors (BCS) often report poor sleep quality and wakefulness throughout the night as the greatest challenges experienced during and posttreatment.

Objectives
This study aimed to elucidate characteristics of sleep disturbances and determine potential predictors that affect sleep disturbances in BCS for 2 years postchemotherapy.

Methods
This is a secondary analysis of data from the EPIGEN study, which longitudinally examined sociodemographic and cancer-related factors, lifestyle, symptom characteristics, and epigenetic factors at baseline prior to chemotherapy (T1), the midpoint (T2), 6-month (T3), 1-year (T4), and 2-year (T5) time points postchemotherapy. Temporal lifestyle changes, symptom characteristics, and epigenetic factors were explored using linear mixed-effects models with a random intercept. A linear regression model was fitted to identify significant predictors of sleep disturbances at each time point.

Results
In 74 BCS with an average age of 51 years and 70% non-Hispanic White, BCS experienced severe sleep disturbances at T2, which gradually improved over time. Significant temporal changes in midsleep awakenings, early awakenings, and fatigue at work were observed, with disturbances being elevated at T2. Anxiety (T1, T2, and T4), fatigue (T3 and T4), and perceived stress (T3) were significant predictors after adjusting for radiation therapy, surgery, and adjuvant endocrine therapy.

Discussion
This study highlights that predictors of sleep disturbances change over time, with anxiety being a factor earlier in the treatment trajectory (prechemotherapy) and continuing over time with fatigue and perceived stress being involved later in the treatment trajectory. Our results indicate that symptom management strategies to address sleep disturbances should be tailored to the temporal factors that may change in severity during active treatment and early survivorship period. Findings gained from this study on sleep disturbance patterns and the potential risk factors can be incorporated into clinical practice in planning education and developing interventions.
Near-point-of-care viral load testing during pregnancy and viremia at delivery
Authors: Joseph Jessica , Boeke Caroline E. , Makadzange Evidence Eve , Sithole Kenny , Maparo Tatenda , Mangwendeza Phibeon Munyaradzi , Peter Trevor , Sacks Jilian A. , Simbi Raiva , Khan Shaukat , Mushavi Angela 
Published: January 2022

Objectives:
Assess whether near-point-of-care (POC) viral load testing at the first antenatal care visit (ANC1) increased the proportion of women taking antiretroviral therapy who were virally suppressed at delivery through expedited clinical action.

Design:
Difference-in-difference analysis.

Methods:
At 20 public sector facilities in Zimbabwe, 10 implemented near-POC viral load testing at ANC1 (August 2019 to November 2020) and 10 used centralized viral load testing at ANC1. Study endpoints included time to result received, clinical action, and unsuppressed viral load (UVL; >1000 copies/ml) at delivery.

Results:
Of 1782 women, only 46% came for ANC1 before their third trimester. Preimplementation, 28% of women received viral load testing at ANC1, increasing to 86% during implementation. In the near-POC viral load arm, women were more likely to receive their result within 30 days of ANC1 sample collection compared with the centralized laboratory arm [54 versus 14%, relative risk (RR): 4.17, 95% confidence interval (CI) 1.82–9.55], as well as receive clinical action among those with UVL (63 versus 8%, RR 7.88; 95% CI 1.53–40.47). However, we did not observe significant changes in risk of UVL at delivery with near-POC viral load (RR 1.02, 95% CI 0.95–1.10).

Conclusion:
ANC1 viral load coverage was initially low. Near-POC viral load testing at ANC1 dramatically improved the timeliness of result receipt by patients and clinical action for those with an UVL. Although we did not observe a significant impact of provision of near-POC viral load at ANC1 on re-suppression at delivery, potentially because of late presentation for ANC1, continued near-POC viral load testing during pregnancy and delivery may reduce UVL and mother-to-child transmission risk.
177Lu-FAPI Therapy in a Patient With End-Stage Metastatic Pancreatic Adenocarcinoma
Authors: Kaghazchi Fatemeh , Aghdam Ramin Akbarian , Haghighi Shirin , Vali Reza , Adinehpour Zohreh 
Published: January 2022

Abstract
A 52-year-old woman with metastatic pancreatic adenocarcinoma underwent imaging with 18F-FDG PET/CT and 68Ga-FAPI-46 PET/CT, which demonstrated malignancy recurrence in the surgical bed with multiple metastatic lesions, more extensive on 68Ga-FAPI-46 PET/CT. The patient was a candidate for therapy with 177Lu-FAPI-46 due to high uptake of lesions in 68Ga-FAPI-46 images and no other available therapeutic option. Posttreatment 177Lu-FAPI-46 scans showed rather rapid washout of the radiopharmaceutical from tumoral lesions. This case report suggests that, although 68Ga-FAPI-46 is a promising agent for tumor imaging, 177Lu-FAPI-46 may not be an optimal compound for theranostic applications.
Increased 18F-ALF-NOTA-FAPI and 18F-FDG Uptake in Renal Angiomyolipoma
Authors: Guo Yue-Hong , Yang Min-Fu 
Published: January 2022

Abstract
Angiomyolipoma is a common benign tumor in the kidney. Previous publication reported that renal angiomyolipoma had very low to low uptake of 18F-FDG. We report a case of pathologically proven angiomyolipoma in the left kidney with intense 18F-FDG and 18F-ALF-NOTA-FAPI uptake.
Unusual Diffuse Ground-Glass Opacities in the Lungs on 18F-FDG PET/CT
Authors: Niu Jinyun , Quan Zhiyong , Zhao Xiaohu , Wang Jing , Kang Fei 
Published: January 2022

Abstract
A 61-year-old man was diagnosed with a malignant melanoma and underwent a resection; he presented with progressive dyspnea after treatment with interferon for 2 months. 18F-FDG PET/CT scan revealed diffuse ground-glass opacities (GGOs) in both lungs with mildly elevated 18F-FDG uptake, similar to that observed with interstitial inflammation. However, a lung biopsy confirmed that the diffuse GGOs were pulmonary metastases of melanoma and were positive for the BRAF mutation. The diffuse GGOs and the progressive dyspnea disappeared after BRAF-targeted therapy. This represents an unusual case of lung metastases from melanoma, mistakenly interpreted as lung inflammation induced by immunotherapy.
Impact of Heparin Preadministration for Detection of Prosthetic Valve Endocarditis With FDG PET/CT
Authors: Soydas Turan Basak , Bozkurt M. Fani 
Published: January 2022

Abstract
A 57-year-old woman with history of aortic and mitral valves replacement was referred to FDG PET/CT before valvular prosthesis renewal surgery. First FDG PET/CT was suboptimal for interpretation due to prominent physiological myocardial FDG uptake, despite patient preparation including 12 hours of fasting and low-carbohydrate, fat-rich diet. Therefore, scan was repeated with IV heparin preadministration at another day and revealed focal FDG uptake on the region of prosthetic heart valves, suggesting endocarditis. FDG PET/CT has been proven to be a useful technique to detect endocarditis, but appropriate patient preparation for adequate suppression of physiological myocardial uptake is important. Heparin preadministration seems to be an important component of patient preparation.
Incidence of Non-Syndromic and Syndromic Craniosynostosis in Sweden
Authors: Tarnow Peter , Kölby Lars , Maltese Giovanni , Söfteland Madiha Bhatti , Lewén Anders , Nilsson Pelle , Enblad Per , Nowinski Daniel 
Published: January 2022

Abstract:
Premature craniosynostosis is a rare condition, with a wide range of incidence estimations in the literature. The aim of this study was to establish the current incidence among the Swedish population. Since the surgical care for these children is centralized to the 2 centers of Sahlgrenska University Hospital and Uppsala University Hospital, the 2 craniofacial hospital registries were examined for surgically treated children, all having a computed tomography verified diagnosis. Results show an incidence of 7.7 cases per 10,000 live births, including 0.60/10,000 syndromic craniosynostosis. Due to information programs among health care staff and a system for early diagnosis through rapid communication, these results seem to mirror the true incidence of craniosynostosis in the Swedish population. The updated incidence data will facilitate healthcare planning and make future studies of possible changes in craniosynostosis incidence more accurate.
The Interaction of Amiodarone and Continuous-flow Left Ventricular Assist Device Use in Risk of Severe Primary Graft Dysfunction Following Heart Transplantation
Authors: Chinnadurai Thiru , Patel Snehal R. , Saeed Omar , Hanif Waqas , Rivas-Lasarte Mercedes , Farooq Muhammad , Castillo Carolyne , Taveras Maria , Fauvel Daphenie , Shin Jooyoung J. , Sims Daniel , Murthy Sandhya , Vukelic Sasha , Chavez Patricia , Forest Stephen , Goldstein Daniel , Jorde Ulrich P. 
Published: January 2022

Background.
Primary graft dysfunction (PGD) increases morbidity and mortality after heart transplant. Here we investigated (1) the association of continuous-flow left ventricular assist device (CF-LVAD), amiodarone, and severe PGD and (2) the safety of amiodarone discontinuation in CF-LVAD patients.

Methods.
Retrospective, single-center study of heart transplant recipients was conducted to investigate the association of risk factors and severe PGD. Patients were grouped into 4 groups based on the presence (denoted +) or absence (denoted –) of amiodarone and CF-LVAD. Prospective amiodarone discontinuation was undertaken to investigate its safety in a cohort of CF-LVAD patients. Study endpoints were severe PGD and recurrence of arrhythmia.

Results.
Severe PGD was strongly associated with CF-LVAD and amiodarone use, and its prevalence is highest if both risk factors were present (CF-LVAD–/amiodarone – 1.5%, CF-LVAD –/amiodarone+ 4.5%, CF-LVAD+/amiodarone – 7.1%, CF-LVAD+/amiodarone+ 21.8%; P < 0.01). The product of every 1-y additional CF-LVAD support by every 100 mg amiodarone was associated with severe PGD (adjusted odds ratio, 1.43; 95% confidence interval, 1.15-1.78; P < 0.01). Amiodarone was prospectively discontinued in 28 CF-LVAD patients. Of them, 6 patients had recurrence of arrhythmia requiring treatment or heart failure admission. There were no deaths. Nine patients in whom amiodarone had been discontinued had heart transplants with no severe PGD.

Conclusions.
Amiodarone and CF-LVAD were independently associated with severe PGD. The combination of both risk factors was associated with a higher prevalence of severe PGD. Amiodarone discontinuation was associated with recurrence of arrhythmia in 6 CF-LVAD patients. There was no mortality associated with amiodarone discontinuation.
Peak Space Motion Artifact Cancellation Applied to Textile Electrode Waist Electrocardiograms Recorded During Outdoors Walking and Jogging
Authors: Hopenfeld Bruce 
Published: January 2022

AbstractBackgroundObtaining reliable rate heart estimates from waist based electrocardiograms (ECGs) poses a very challenging problem due to the presence of extreme motion artifacts. The literature reveals few, if any, attempts to apply motion artifact cancellation methods to waist based ECGs. This paper describes a new methodology for ameliorating the effects of motion artifacts in ECGs by specifically targeting ECG peaks for elimination that are determined to be correlated with accelerometer peaks. This peak space cancellation is applied to real world waist based ECGs.Algorithm SummaryThe methodology includes successive applications of a previously described pattern-based heart beat detection scheme (Temporal Pattern Search, or “TEPS”). In the first application, TEPS is applied to accelerometer signals recorded contemporaneously with ECG signals to identify high-quality accelerometer peak sequences (SA) indicative of quasi-periodic motion likely to impair identification of peaks in a corresponding ECG signal. The process then performs ECG peak detection and locates the closest in time ECG peak to each peak in an SA. The differences in time between ECG and SA peaks are clustered. If the number of elements in a cluster of peaks in an SA exceeds a threshold, the ECG peaks in that cluster are removed from further processing. After this peak removal process, further QRS detection proceeds according to TEPS.ExperimentThe above procedure was applied to data from real world experiments involving four sessions of walking and jogging on a dirt road for approximately 20-25 minutes. A compression shirt with textile electrodes served as the ground truth recording. A textile electrode based chest strap was worn around the waist to generate a single channel signal upon which to test peak space cancellation/TEPS.ResultsBoth walking and jogging heart rates were generally well tracked. In the four recordings, the percentage of segments within 10 beats/minute of reference was 96%, 99%, 92% and 96%. The percentage of segments within 5 beats/minute of reference was 86%, 90%, 82% and 78%. There was very good agreement between the RR intervals associated with the reference and waist recordings. For acceptable quality segments, the root mean square sum of successive RR interval differences (RMSSD) was calculated for both the reference and waist recordings. Next, the difference between waist and reference RMSSDs was calculated (ΔRMSSD). The mean ΔRMSSD (over acceptable segments) was 4.6 m, 5.2 ms, 5.2 ms and 6.6 ms for the four recordings. Given that only one waist ECG channel was available, and that the strap used for the waist recording was not tailored for that purpose, the proposed methodology shows promise for waist based sinus rhythm QRS detection.
Epigenomic mapping identifies a super-enhancer repertoire that regulates cell identity in bladder cancers through distinct transcription factor networks
Authors: Neyret-Kahn Hélène , Fontugne Jacqueline , Meng Xiang Yu , Groeneveld Clarice S. , Cabel Luc , Ye Tao , Guyon Elodie , Krucker Clémentine , Dufour Florent , Chapeaublanc Elodie , Rapinat Audrey , Jeffery Daniel , Neuzillet Yann , Lebret Thierry , Gentien David , Davidson Irwin , Allory Yves , Bernard-Pierrot Isabelle , Radvanyi François 
Published: January 2022

AbstractMuscle-invasive bladder cancer (BLCA) is an aggressive disease. Consensus BLCA transcriptomic subtypes have been proposed, with two major Luminal and Basal subgroups, presenting distinct molecular and clinical characteristics. However, how these distinct subtypes are regulated remains unclear. We hypothesized that epigenetic activation of distinct super-enhancers could drive the transcriptional programs of BLCA subtypes.Through integrated RNA-sequencing and epigenomic profiling of histone marks in primary tumours, cancer cell lines, and normal human urothelia, we established the first integrated epigenetic map of BLCA and demonstrated the link between subtype and epigenetic control. We identified the repertoire of activated super-enhancers and highlighted Basal, Luminal and Normal-associated SEs. We revealed the super-enhancer-regulated networks of candidate master transcription factors for Luminal and Basal subgroups including FOXA1 and ZBED2 respectively. FOXA1 CRISPR-Cas9 mutation triggered a shift from Luminal to Basal phenotype, confirming its role in Luminal identity regulation and induced ZBED2 overexpression. In parallel, we showed that both FOXA1 and ZBED2 play concordant roles in preventing inflammatory response in cancer cells through STAT2 inhibition.Our study furthers the understanding of epigenetic regulation of muscle-invasive BLCA and identifies a co-regulated network of super-enhancers and associated transcription factors providing potential targets for the treatment of this aggressive disease.